Diabetes Care Impact Factor

The trajectory is encouraging. After dipping to 14.8 in 2023, Diabetes Care bounced back to 16.6 in 2024. This may reflect the growing citation activity around GLP-1 receptor agonists, continuous glucose monitoring studies, and diabetes prevention research, all of which are hot areas in the diabetes care literature.

For authors, 16.6 is a strong number that places Diabetes Care firmly in the upper tier of clinical endocrinology and metabolism.

Diabetes Care's JIF is heavily influenced by the ADA Standards of Care, which is published in the journal and is one of the most cited documents in all of diabetes medicine. That editorial feature helps boost the overall JIF, but it also means individual research papers may have lower per-article citation performance than the JIF suggests. This is worth keeping in mind when using the JIF to set expectations for your own paper.

Despite that caveat, Diabetes Care's community reach is hard to match. The ADA readership includes virtually every endocrinologist and diabetes specialist in North America, plus a large primary care audience that follows ADA guidance. A paper in Diabetes Care reaches the people who make treatment decisions for the world's largest diabetes patient population.

In our pre-submission review work with clinical manuscripts targeting Diabetes Care, three rejection patterns appear more consistently than any others.

Basic science routed to the wrong journal. Diabetes Care's Instructions for Authors state the journal "does not publish descriptions of study designs without data, papers on in vitro studies, or studies involving animals." This is a hard exclusion, not a scope preference. Manuscripts describing mouse model pharmacology, cell line mechanistic work, or animal model interventions without a human clinical dataset will be returned without peer review. The distinction matters because Diabetes, the ADA's other flagship journal, does publish experimental diabetes research. Authors with strong translational work but no human-facing dataset should evaluate Diabetes or Cell Metabolism first.

Studies where the clinical implication is indirect. The most common pattern we see in manuscripts targeting Diabetes Care is diabetes-related science that does not connect to a clinical decision. Editors screen for work that will "rapidly impact practice and clinical research", not just add to existing knowledge. A study documenting that a metabolic biomarker is elevated in patients with poorly controlled T2D without demonstrating that knowing the biomarker changes a clinical action typically fails this filter. The distinction is consequential: Diabetes Care wants the "so what for the clinician" to be visible in the abstract, not reconstructed by reviewers. If you need to write a paragraph explaining how the finding might eventually inform practice, the manuscript is probably not ready for this journal in its current form.

Underpowered or protocol-deviant trial reports. Diabetes Care explicitly requires that statistical design and power calculations be described in detail, and the editorial guidelines note that "futile studies that produce subject risk without enrollment sufficient to address the research objective" are rejected at desk review. Trial manuscripts that deviate substantially from registered protocols without explanation, or that report outcomes with wide confidence intervals reflecting enrollment shortfalls, face early rejection. Diabetes Care's acceptance rate of approximately 18% means the journal can consistently pass over well-intentioned studies that lack the evidence density to drive clinical recommendations. A Diabetes Care submission readiness check can identify whether the study design, sample size, and clinical framing are calibrated for this bar before submission.

Diabetes Care editors want work that changes how diabetes is managed in practice. That means:

• clinical trials with direct management implications
• epidemiological data that informs risk assessment or screening
• technology and device studies for glucose management (CGM, insulin delivery, etc.)
• guideline-relevant evidence from well-designed studies
• studies that address real-world diabetes care questions

What gets filtered: primarily mechanistic or basic science work (that belongs in Diabetes or Cell Metabolism), small underpowered studies, and papers where the clinical relevance is indirect.

This page should help the searcher answer a practical placement question: is the manuscript truly built for a clinical diabetes-care audience, or is it better framed for a broader endocrinology journal, a mechanistic metabolism journal, or a general-medicine venue? Diabetes Care is powerful because its readership is tightly aligned with how diabetes is actually managed. That makes the journal valuable when the paper changes care, not just when it reports an interesting diabetes-related result.

The metric helps because it confirms the journal is still one of the most visible homes in clinical diabetes. But editorial fit is about actionability. Papers do well here when endocrinologists, guideline writers, diabetes educators, or device-focused clinicians can use the result to adjust risk thinking, therapeutic choices, monitoring, or implementation. If the paper's importance depends on basic biology, broad metabolism, or generalized endocrine relevance, the JIF is not the main reason to submit here.

The rebound after the 2023 dip is useful context because it shows the journal is still accumulating attention in fast-moving clinical areas such as GLP-1 therapies, continuous glucose monitoring, obesity overlap, and prevention. But the trend matters most as a sign of durable clinical influence, not as a vanity statistic. Authors deciding between Diabetes Care, Diabetologia, Lancet Diabetes & Endocrinology, or NEJM should use the trend to place the journal correctly in the clinical tier, then judge fit by practice relevance and study strength.

• It helps when the paper directly informs diabetes management, screening, monitoring, or therapeutic decision-making.
• It helps when the intended readers are clinicians and care teams rather than basic-science metabolism audiences.
• It misleads when the work is mainly mechanistic, exploratory, or broad endocrinology without enough diabetes-care consequence.
• It misleads when authors treat the ADA brand as enough to overcome weak clinical actionability.

• Diabetes Care submission guide
• Diabetes Care submission process
• How to avoid desk rejection at Diabetes Care
• Is Diabetes Care a good journal?

The impact factor for Diabetes Care measures average citations per paper over 2 years. It does not measure the quality of any individual paper, the prestige within a specific subfield, or whether the journal is the right fit for your work. A high IF does not guarantee your paper will be cited, and a lower IF does not mean the journal lacks influence in its specialty.

Impact factors also do not account for field-specific citation patterns. Journals in clinical medicine accumulate citations faster than journals in mathematics or ecology. Comparing IFs across fields is misleading.

Before choosing this journal based on IF alone, a Diabetes Care submission readiness check assesses whether your manuscript fits the journal's actual editorial scope.